期刊
ANESTHESIA AND ANALGESIA
卷 111, 期 3, 页码 707-709出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1213/ANE.0b013e3181eac1c9
关键词
-
资金
- Department of Anesthesiology, Emory University
Loss of skeletal muscle mass is a poorly understood complication of end-stage liver disease (ESLD). Based on recent stem cell literature, we hypothesized that the potent negative regulator of muscle mass, myostatin, could play a role in the muscle loss associated with ESLD. In this preliminary investigation, we measured myostatin levels in patients undergoing liver transplant evaluation, using a novel enzyme-linked immunosensitivity assay. Myostatin levels were significantly elevated in patients with ESLD compared with healthy controls. These data suggest that myostatin deserves further investigation as a target for therapies designed to preserve muscle mass in patients with ESLD. (Anesth Analg 2010;111:707-9)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据